Our results (Tables 2–4) demonstrated that a lower SM-RA was an independent risk predictor for treatment failure, shorter PFS and OS, in this cohort of HCC patients, after adjusting all other risk factors, including gender, age, HGB, Scr, and VFmean (AOR=1.21, 95% CI: 1.02-1.44, P=0.033; AHR for PFS=0.92, 95%CI: 0.85-0.99, P=0.023; AHR for OS=0.91, 95%CI: 0.84-0.98, P=0.012). This evidence concerns the gene CYGB and hepatocellular carcinoma.